A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 249 participants.

Also called NCT07647133

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 249 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07647133
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07647133. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-15 (anticipated); primary completion 2027-10-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease
Intervention (Drug)
SAL0140 Tablets
Intervention (Drug)
SAL0140 Tablets
Intervention (Drug)
SAL0140 placebo
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07647133
Content hash
8da8ae5506e1c383fa005417c7d3b1771a1a347f3b848e127d5423901711497f